Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles

BackgroundNovel vector control methods that can directly target outdoor malaria transmission are urgently needed in the Greater Mekong Subregion (GMS) to accelerate malaria elimination and artemisinin resistance containment efforts. Ivermectin mass drug administration (MDA) to humans has been shown to effectively kill wild Anopheles and suppress malaria transmission in West Africa. Preliminary laboratory investigations were performed to determine ivermectin susceptibility and sporontocidal effect in GMS Anopheles malaria vectors coupled with pharmacokinetic models of ivermectin at escalating doses.MethodsA population-based pharmacokinetic model of ivermectin was developed using pre-existing data from a clinical trial conducted in Thai volunteers at the 200 µg/kg dose. To assess ivermectin susceptibility, various concentrations of ivermectin compound were mixed in human blood meals and blood-fed to Anopheles dirus, Anopheles minimus, Anopheles sawadwongporni, and Anopheles campestris. Mosquito survival was monitored daily for 7 days and a non-linear mixed effects model with probit analyses was used to calculate concentrations of ivermectin that killed 50% (LC50) of mosquitoes for each species. Blood samples were collected from Plasmodium vivax positive patients and offered to mosquitoes with or without ivermectin at the ivermectin LC25 or LC5 for An. dirus and An. minimus.ResultsThe GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC50 = 16.3 ng/ml) > An. campestris (LC50 = 26.4 ng/ml) = An. sawadwongporni (LC50 = 26.9 ng/ml) > An. dirus (LC50 = 55.6 ng/ml). Mosquito survivorship results, the pharmacokinetic model, and extensive safety data indicated that ivermectin 400 µg/kg is the ideal minimal dose for MDA in the GMS for malaria parasite transmission control. Ivermectin compound was sporontocidal to P. vivax in both An. dirus and An. minimus at the LC25 and LC5 concentrations.ConclusionsIvermectin is lethal to dominant GMS Anopheles malaria vectors and inhibits sporogony of P. vivax at safe human relevant concentrations. The data suggest that ivermectin MDA has potential in the GMS as a vector and transmission blocking control tool to aid malaria elimination efforts.

[1]  S. Chanteau,et al.  Ivermectin 400 μg/kg: long-term suppression of microfilariae in Bancroftian filariasis , 1994 .

[2]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[3]  Kevin C. Kobylinski,et al.  Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors , 2010, Malaria Journal.

[4]  J. Sattabongkot,et al.  Comparison of artificial membrane feeding with direct skin feeding to estimate the infectiousness of Plasmodium vivax gametocyte carriers to mosquitoes. , 2003, The American journal of tropical medicine and hygiene.

[5]  Massamba Sylla,et al.  The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. , 2010, Acta tropica.

[6]  G. Weil,et al.  Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  N. Opoku,et al.  The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  J. Rizzo,et al.  Treatment of bancroftian filariasis in Recife, Brazil: a two-year comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[9]  Wojtek S. Kuklinski,et al.  Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals , 2015, BMC Genomics.

[10]  D. Addiss,et al.  Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia. , 1993, The American journal of tropical medicine and hygiene.

[11]  Kevin C Kobylinski,et al.  Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae , 2012, Malaria Journal.

[12]  D. Addiss,et al.  Direct assessment in vivo of the efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  G Dreyer,et al.  Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  Pierre Defourny,et al.  The Anopheles dirus complex: spatial distribution and environmental drivers , 2007, Malaria Journal.

[15]  Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects , 2002, Journal of clinical pharmacology.

[16]  Reversal of meticillin resistance in Staphylococcus aureus by the anthelmintic avermectin. , 2014, International journal of antimicrobial agents.

[17]  Teun Bousema,et al.  Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.

[18]  N. L. Nguyen,et al.  Control of bancroftian filariasis in an endemic area of Polynesia by ivermectin 400 μg/kg , 1996 .

[19]  E. Stapley,et al.  Isolation and Characterization of the Producing Organism , 1989 .

[20]  M. Alpers,et al.  Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes , 1998, The Lancet.

[21]  M. Bangs,et al.  Anopheles species diversity and distribution of the malaria vectors of Thailand. , 2015, Trends in parasitology.

[22]  T. Lefèvre,et al.  Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria , 2015, Malaria Journal.

[23]  B. Foy,et al.  Ivermectin: a complimentary weapon against the spread of malaria? , 2017, Expert review of anti-infective therapy.

[24]  Teun Bousema,et al.  Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Teun Bousema,et al.  The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. , 2014, The Journal of infectious diseases.

[26]  P. E. Simonsen,et al.  Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus , 2015, Parasites & Vectors.

[27]  P. Hotez,et al.  Neglected Tropical Diseases among the Association of Southeast Asian Nations (ASEAN): Overview and Update , 2015, PLoS neglected tropical diseases.

[28]  Kevin C. Kobylinski,et al.  Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. , 2011, The American journal of tropical medicine and hygiene.

[29]  S. Kietinun,et al.  Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  E. Walker,et al.  Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. , 2009, Annals of tropical medicine and parasitology.

[31]  Hannah C. Slater,et al.  Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals , 2016, Science Translational Medicine.

[32]  P. Somboon,et al.  Susceptibility of Anopheles campestris-like and Anopheles barbirostris species complexes to Plasmodium falciparum and Plasmodium vivax in Thailand. , 2011, Memorias do Instituto Oswaldo Cruz.

[33]  B. Giraudeau,et al.  Oral ivermectin versus malathion lotion for difficult-to-treat head lice. , 2010, The New England journal of medicine.

[34]  Sinuon Muth,et al.  Strongyloides stercoralis infection and re-infection in a cohort of children in Cambodia. , 2014, Parasitology international.

[35]  P. Glaziou,et al.  Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis. , 1995, The Southeast Asian journal of tropical medicine and public health.

[36]  M. Coosemans,et al.  Behavioural heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector control , 2005, Tropical medicine & international health : TM & IH.

[37]  Ruben O. Conner,et al.  Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial , 2016, The Journal of infectious diseases.

[38]  Á. Irigoyen,et al.  Pilot Study of a Slow-Release Ivermectin Formulation for Malaria Control in a Pig Model , 2016, Antimicrobial Agents and Chemotherapy.

[39]  G. Christophides,et al.  Microbiota-induced peritrophic matrix regulates midgut homeostasis and prevents systemic infection of malaria vector mosquitoes , 2017, PLoS pathogens.

[40]  M. Alpers,et al.  Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. , 1993, The American journal of tropical medicine and hygiene.

[41]  A. Hightower,et al.  Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children , 1997, The Lancet.

[42]  P. Vounatsou,et al.  High Prevalence and Spatial Distribution of Strongyloides stercoralis in Rural Cambodia , 2014, PLoS neglected tropical diseases.

[43]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[44]  G. Weil,et al.  Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[45]  Hannah C. Slater,et al.  Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda , 2015, Malaria Journal.

[46]  J. Lines,et al.  Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. , 2010, The Journal of infectious diseases.

[47]  Kevin C. Kobylinski,et al.  Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments , 2014, Malaria Journal.

[48]  T. Klein,et al.  The relationship between wing length, blood meal volume, and fecundity for seven colonies of Anopheles species housed at the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. , 2015, Acta tropica.

[49]  S. Chanteau,et al.  Ivermectin plus diethylcarbamazine: an additive effect on early microfilarial clearance. , 1994, The American journal of tropical medicine and hygiene.

[50]  K. Ramaiah,et al.  Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  J. Okeibunor,et al.  Where would I be without ivermectin? Capturing the benefits of community‐directed treatment with ivermectin in Africa , 2011, Tropical medicine & international health : TM & IH.

[52]  D. Addiss,et al.  A new tool to assess the adulticidal efficacy in vivo of antifilarial drugs for bancroftian filariasis. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  G. Dimopoulos,et al.  Natural Microbe-Mediated Refractoriness to Plasmodium Infection in Anopheles gambiae , 2011, Science.

[54]  H. Guzmán,et al.  Effect of ivermectin on the ovarian development of Aedes aegypti (Diptera: Culicidae). , 1991, Journal of medical entomology.

[55]  D. Ojcius,et al.  Ivermectin Inhibits Growth of Chlamydia trachomatis in Epithelial Cells , 2012, PloS one.

[56]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[57]  Kevin C. Kobylinski,et al.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. , 2014, The American journal of tropical medicine and hygiene.

[58]  E. Konishi,et al.  Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. , 1996, The American journal of tropical medicine and hygiene.

[59]  N. Opoku,et al.  The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. , 1995, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[60]  D. Remick,et al.  Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin. , 1999, The Journal of infectious diseases.

[61]  T. Geary,et al.  Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus , 1996, European Journal of Clinical Pharmacology.

[62]  M. Boussinesq,et al.  Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial , 2002, The Lancet.

[63]  D. Addiss,et al.  Ultrasonographic assessment of the adulticidal efficacy of repeat high‐dose ivermectin in bancroftian filariasis , 1996, Tropical medicine & international health : TM & IH.

[64]  Y. Suputtamongkol,et al.  Efficacy and Safety of Single and Double Doses of Ivermectin versus 7-Day High Dose Albendazole for Chronic Strongyloidiasis , 2011, PLoS neglected tropical diseases.

[65]  P. Glaziou,et al.  Advantages of ivermectin at a single dose of 400 μg/kg compared with 100 μg/kg for community treatment of lymphatic filariasis in Polynesia , 1994 .

[66]  C. Knirsch,et al.  The Effect of Azithromycin on Ivermectin Pharmacokinetics—A Population Pharmacokinetic Model Analysis , 2008, PLoS neglected tropical diseases.

[67]  Duolao Wang,et al.  Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya , 2016, JMIR research protocols.

[68]  Jos H. Beijnen,et al.  Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM , 2011, Comput. Methods Programs Biomed..

[69]  A. Dondorp,et al.  Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance , 2015, Expert review of anti-infective therapy.

[70]  G. Weil,et al.  Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[71]  J. Chodakewitz,et al.  Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. , 1993, The American journal of tropical medicine and hygiene.

[72]  M. Fay,et al.  Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  S. Chanteau,et al.  Results of a safety trial on single-dose treatments with 400 mcg/kg of ivermectin in bancroftian filariasis. , 1992, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[74]  M. Bangs,et al.  Host feeding patterns and preference of Anopheles minimus (Diptera: Culicidae) in a malaria endemic area of western Thailand: baseline site description , 2012, Parasites & Vectors.

[75]  P. Odermatt,et al.  Epidemiology of Strongyloides stercoralis on Mekong islands in southern Laos. , 2015, Acta tropica.

[76]  C. Vilchèze,et al.  Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains , 2012, Antimicrobial Agents and Chemotherapy.

[77]  N. Speybroeck,et al.  Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control , 2010, Malaria Journal.

[78]  B. Arison,et al.  Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[79]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.